Clinuvel Pharmaceuticals Limited

ASX:CUV Stok Raporu

Piyasa değeri: AU$684.3m

Clinuvel Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Clinuvel Pharmaceuticals yıllık ortalama 15.8% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 12.3% annual. Gelirler growing yılda ortalama 22.9% oranında artmaktadır. Clinuvel Pharmaceuticals'in özkaynak karlılığı 17.6% ve net marjı 40.4%'dir.

Anahtar bilgiler

15.8%

Kazanç büyüme oranı

15.4%

EPS büyüme oranı

Biotechs Sektör Büyümesi9.6%
Gelir büyüme oranı22.9%
Özkaynak getirisi17.6%
Net Marj40.4%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Aug 11
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jun 27
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

May 09
Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Mar 24
Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18
An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20
Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30
Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27
Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14
Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03
This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23
A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23
Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10
With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06
Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27
Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20
What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01
Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14
Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28
We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21
What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Gelir ve Gider Dağılımı

Clinuvel Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

ASX:CUV Gelir, gider ve kazançlar (AUD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 248836292
31 Mar 248533292
31 Dec 238230291
30 Sep 238030271
30 Jun 237831251
31 Mar 237429231
31 Dec 227026211
30 Sep 226824201
30 Jun 226621191
31 Mar 226222181
31 Dec 215724171
30 Sep 215324161
30 Jun 214825141
31 Mar 21432314-1
31 Dec 20382114-3
30 Sep 20351813-1
30 Jun 203315120
31 Mar 203215104
31 Dec 19321588
30 Sep 19321677
30 Jun 19311867
31 Mar 19291767
31 Dec 18271666
30 Sep 18261566
30 Jun 18251366
31 Mar 18211065
31 Dec 1717665
30 Sep 1717764
30 Jun 1717754
31 Mar 1714554
31 Dec 1612344
30 Sep 169044
30 Jun 167-354
31 Mar 165-533
31 Dec 154-623
30 Sep 154-843
30 Jun 153-1063
31 Mar 153-1083
31 Dec 143-1093
30 Sep 143-873
30 Jun 143-653
31 Mar 143-653
31 Dec 132-653

Kaliteli Kazançlar: CUV yüksek düzeyde nakit dışı kazança sahiptir.

Büyüyen Kar Marjı: CUV 'nin mevcut net kar marjları (40.4%) geçen yılın (39.1%) sinden daha yüksektir.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CUV şirketinin kazancı son 5 yılda yılda 15.8% oranında arttı.

Büyüme Hızlandırma: CUV 'un son bir yıldaki kazanç büyümesi ( 16.4% ) 5 yıllık ortalamasını (yıllık 15.8% ) aşıyor.

Kazançlar vs. Sektör: CUV geçen yılki kazanç büyümesi ( 16.4% ) Biotechs sektörünün 2.5% değerini aştı.


Özkaynak Getirisi

Yüksek ROE: CUV 'nin Özsermaye Getirisi ( 17.6% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin